[go: up one dir, main page]

WO2013106766A3 - Indications thérapeutiques du miarn-1291 - Google Patents

Indications thérapeutiques du miarn-1291 Download PDF

Info

Publication number
WO2013106766A3
WO2013106766A3 PCT/US2013/021307 US2013021307W WO2013106766A3 WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3 US 2013021307 W US2013021307 W US 2013021307W WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
methods
therapeutic indications
conditions
human diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/021307
Other languages
English (en)
Other versions
WO2013106766A2 (fr
Inventor
Aiming Yu
Yuzhuo PAN
Jingxin Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Research Foundation of the State University of New York
Original Assignee
Health Research Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc, Research Foundation of the State University of New York filed Critical Health Research Inc
Publication of WO2013106766A2 publication Critical patent/WO2013106766A2/fr
Publication of WO2013106766A3 publication Critical patent/WO2013106766A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne dans des compositions et des procédés destinés à la prévention et au traitement de maladies et/ou d'états humain(e)s. La présente invention concerne, entre autres, la reconstitution de niveaux de miARN-1291 dans des échantillons et chez des sujets. Des procédés destinés au diagnostic et au traitement de maladies et d'états humain(e)s par l'évaluation des niveaux d'expression du miARN -1291 sont également décrits. Des procédés de traitement de cancers humains par modification ou régulation des voies du miARN sont également décrits.
PCT/US2013/021307 2012-01-13 2013-01-11 Indications thérapeutiques du miarn-1291 Ceased WO2013106766A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586446P 2012-01-13 2012-01-13
US61/586,446 2012-01-13

Publications (2)

Publication Number Publication Date
WO2013106766A2 WO2013106766A2 (fr) 2013-07-18
WO2013106766A3 true WO2013106766A3 (fr) 2013-09-12

Family

ID=48782096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/021307 Ceased WO2013106766A2 (fr) 2012-01-13 2013-01-11 Indications thérapeutiques du miarn-1291

Country Status (1)

Country Link
WO (1) WO2013106766A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7026440B2 (ja) 2014-05-28 2022-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法
US10422003B2 (en) 2015-03-23 2019-09-24 The Regents Of The University Of California Methods for detection of RNase activity
CN105106959B (zh) * 2015-08-16 2018-07-17 深圳市倍昂生物科技有限公司 虫草素在制备与放疗和/或化疗协同治疗肿瘤的药物中的应用以及一种药物组合物
JP6842779B2 (ja) * 2016-10-31 2021-03-17 国立大学法人岐阜大学 二本鎖核酸分子、およびその用途
CN118512469A (zh) * 2019-02-26 2024-08-20 首尔大学校产学协力团 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
CN114891742B (zh) * 2022-06-23 2024-06-04 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (fr) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation de l'expression génique par ciblage d'un petit arn endogène de promoteurs de gènes
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
WO2010139810A1 (fr) * 2009-06-05 2010-12-09 Febit Holding Gmbh Empreinte de micro-arn utilisée dans le diagnostic du cancer du poumon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (fr) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation de l'expression génique par ciblage d'un petit arn endogène de promoteurs de gènes
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
WO2010139810A1 (fr) * 2009-06-05 2010-12-09 Febit Holding Gmbh Empreinte de micro-arn utilisée dans le diagnostic du cancer du poumon

Also Published As

Publication number Publication date
WO2013106766A2 (fr) 2013-07-18

Similar Documents

Publication Publication Date Title
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EP4424326A3 (fr) Cellules nk-92 modifiées pour traiter le cancer
ZA201503110B (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2012083132A3 (fr) Diagnostic et traitements associés à l'inhibition de th2
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
WO2012006421A3 (fr) Diagnostic et traitement du cancer du sein
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
WO2013106766A3 (fr) Indications thérapeutiques du miarn-1291
WO2014152754A3 (fr) Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
WO2010101793A3 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2017011356A3 (fr) Procédés et compositions pour traiter des maladies et des états induits par des médicaments
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
WO2012078648A3 (fr) Nouvelle méthode de diagnostic et de pronostic du cancer et prédiction de la réponse à une thérapie
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2